# Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

> **NCT04092673** · PHASE1,PHASE2 · RECRUITING · sponsor: **Effector Therapeutics** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** eFT226
- **DRUG:** Sotorasib
- **DRUG:** Fulvestrant
- **DRUG:** Abemaciclib
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT04092673
- **Lead sponsor:** Effector Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-25
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04092673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04092673, "Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04092673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*